RxDoctor Payments Data

Suneeta Krishnareddy, MD

Gastroenterology · New York, NYNPI 1013233725

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $7,722 of the $8,483 with a category attached, or 91.0%. Sanofi US Services Inc. accounts for 91.0% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $7,890, more than ten times the $173 reported in 2022.

$8,483in general payments, 2019–2025

Across 26 payments — averaging $326.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$8K
  • Johnson & Johnson$272
  • AbbVie$185
  • Lilly USA, LLC$168
  • Medtronic$108
  • QOL Medical, LLC$28
$513,062in research payments, 2019–2025

Across 87 payments — averaging $5897.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$504K
  • Boehringer Ingelheim International GmbH$9K

What the payments were for

  • Consulting fees$7,72291%
  • Food & beverage$6388%
  • Education$1231%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,483 in reported general payments places this provider in the 75th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$39,152
Medicare patients
137
Services billed
281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide32$16,609
Mesalamine15$2,111
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates17$940
Esomeprazole Magnesium23$399
Omeprazole68$376
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl26$346
Dicyclomine Hcl22$308
Famotidine23$276
Pantoprazole Sodium20$217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$185$16,60932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →